Updates are available Correction dated 2024-02-23
Click to view Correction: https://doi.org/10.1038/s41588-024-01680-3
-
Authors
Chang, Liang https://orcid.org/0000-0002-5653-3004
Jung, Nancy Y. https://orcid.org/0000-0003-4089-0717
Atari, Adel
Rodriguez, Diego J. https://orcid.org/0000-0002-0053-8674
Kesar, Devishi
Song, Tian-Yu https://orcid.org/0000-0001-9834-6795
Rees, Matthew G. https://orcid.org/0000-0002-2987-7581
Ronan, Melissa https://orcid.org/0000-0003-4269-1404
Li, Ruitong
Ruiz, Paloma https://orcid.org/0000-0001-6208-5087
Chaturantabut, Saireudee
Ito, Takahiro
van Tienen, Laurens M.
Tseng, Yuen-Yi
Roth, Jennifer A. https://orcid.org/0000-0002-5117-5586
Sellers, William R. https://orcid.org/0000-0002-3539-9803
- License Information
-
More Information
Article History
Received: 20 December 2022
Accepted: 22 August 2023
First Online: 25 September 2023
Change Date: 23 February 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41588-024-01680-3
Competing interests
: W.R.S. is a Board or SAB member and holds equity in Ideaya Biosciences, Civetta Therapeutics, Red Ridge Bio, Delphia Therapeutics, Scorpion Therapeutics and 2Seventy Bio. Delphia Therapeutics is exploring GOF therapeutics in cancer. W.R.S. has consulted for Array, Astex, Epidarex Capital, Ipsen, PearlRiver Therapeutics, Merck Pharmaceuticals, Sanofi, Servier and Syndax Pharmaceuticals and receives research funding from Pfizer Pharmaceuticals, Merck Pharmaceuticals, Ideaya Biosciences, Calico, Boehringer-Ingelheim, Bristol Myers Squibb, Bayer Pharmaceuticals, Novartis Institutes for Biomedical Research and Ridgeline Discovery. W.R.S. is a copatent holder on EGFR mutation diagnostic patents. L.C. is an employee of Cure Ventures and was a previous employee of 5AM Ventures and Flagship Pioneering. T.I. is an equity holder of Scorpion Therapeutics and Odyssey Therapeutics. All other authors declare no competing interests.
